Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Accumulated Expenses (2016 - 2018)

Northwest Biotherapeutics (NWBO) has 5 years of Other Accumulated Expenses data on record, last reported at $6.2 million in Q3 2018.

  • For Q3 2018, Other Accumulated Expenses changed 0.0% year-over-year to $6.2 million; the TTM value through Sep 2018 reached $6.2 million, changed 0.0%, while the annual FY2017 figure was $6.2 million, 0.0% changed from the prior year.
  • Other Accumulated Expenses reached $6.2 million in Q3 2018 per NWBO's latest filing, roughly flat from $6.2 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $6.2 million in Q4 2014 and bottomed at $6.2 million in Q4 2014.
  • Average Other Accumulated Expenses over 5 years is $6.2 million, with a median of $6.2 million recorded in 2014.
  • The widest YoY moves for Other Accumulated Expenses: up 0.0% in 2015, down 0.0% in 2015.
  • A 5-year view of Other Accumulated Expenses shows it stood at $6.2 million in 2014, then changed by 0.0% to $6.2 million in 2015, then changed by 0.0% to $6.2 million in 2016, then changed by 0.0% to $6.2 million in 2017, then changed by 0.0% to $6.2 million in 2018.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $6.2 million in Q3 2018, $6.2 million in Q2 2018, and $6.2 million in Q1 2018.